Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AY1I
|
|||
| Former ID |
DIB015649
|
|||
| Drug Name |
GSK-2315698
|
|||
| Synonyms |
GSK-2315698A; Serum amyloid P depleter (iv, amyloidosis), GlaxoSmithKline
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Amyloidosis [ICD-11: 5D00; ICD-9: 277.3] | Phase 1 | [1] | |
| Company |
GlaxoSmithKline plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serum amyloid P-component (APCS) | Target Info | . | [2], [3] |
| Reactome | Amyloid formation | |||
| WikiPathways | Human Complement System | |||
| Amyloids | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health. | |||
| REF 2 | Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15. | |||
| REF 3 | PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.